Cargando…

Circulating tumour DNA analysis in multiple myeloma

Detalles Bibliográficos
Autores principales:	Mithraprabhu, Sridurga, Spencer, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710860/ https://www.ncbi.nlm.nih.gov/pubmed/29207579 http://dx.doi.org/10.18632/oncotarget.21595

Ejemplares similares

Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2018)

DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients
por: Mithraprabhu, Sridurga, et al.
Publicado: (2019)

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2023)

Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients
por: Chen, Maoshan, et al.
Publicado: (2019)

Translational Potential of RNA Derived From Extracellular Vesicles in Multiple Myeloma
por: Reale, Antonia, et al.
Publicado: (2021)

Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies
por: Hocking, Jay, et al.
Publicado: (2016)

Deactylase inhibition in myeloproliferative neoplasms
por: Mithraprabhu, Sridurga, et al.
Publicado: (2010)

Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2020)

Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton
por: Mithraprabhu, S, et al.
Publicado: (2014)

Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo
por: Savvidou, Ioanna, et al.
Publicado: (2022)

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates
por: Kis, Olena, et al.
Publicado: (2017)

Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
por: Qiang, Wanting, et al.
Publicado: (2023)

Heavy menstrual bleeding and dysmenorrhea are improved by Magnetic Resonance Guided Focused Ultrasound Surgery (MRgFUS) of adenomyosis
por: Jayaram, Ramya, et al.
Publicado: (2016)

Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma
por: Zhang, Liangxuan, et al.
Publicado: (2016)

Circulating Tumour Cells, Cell Free DNA and Tumour-Educated Platelets as Reliable Prognostic and Management Biomarkers for the Liquid Biopsy in Multiple Myeloma
por: Allegra, Alessandro, et al.
Publicado: (2022)

Sperm chromatin structure assay versus sperm chromatin dispersion kits: Technical repeatability and choice of assisted reproductive technology procedure
por: B, Vidya Laxme, et al.
Publicado: (2020)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Hyperhaploid karyotypes in multiple myeloma
por: Sawyer, Jeffrey R., et al.
Publicado: (2017)

Novel therapies for multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Latest Development in Multiple Myeloma
por: Imai, Yoichi
Publicado: (2020)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Clinical Significance of Circulating Cell-Free DNA Detection in Multiple Myeloma: A Meta-Analysis
por: Ye, Xueshi, et al.
Publicado: (2022)

Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer
por: Abbosh, C, et al.
Publicado: (2018)

Cancer drug resistance in multiple myeloma
por: Uckun, Fatih M.
Publicado: (2022)

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

Multiple mechanisms can disrupt oncogenic pathways in multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2018)

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
por: Oberle, Anna, et al.
Publicado: (2017)

Circulating microRNAs and Their Role in Multiple Myeloma
por: Federico, Cinzia, et al.
Publicado: (2019)

Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma
por: Manier, S., et al.
Publicado: (2018)

The level and integrity of plasma circulating cell-free DNA in patients with primary multiple myeloma
por: Shen, Qian, et al.
Publicado: (2022)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013)

Methods for reducing delays in the diagnosis of multiple myeloma
por: Koshiaris, Constantinos
Publicado: (2019)

Recent Advances on the Pathobiology and Treatment of Multiple Myeloma
por: Amodio, Nicola
Publicado: (2021)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients
por: Levin, Nancy, et al.
Publicado: (2016)

Development of circulating tumour DNA analysis for gastrointestinal cancers
por: Nakamura, Yoshiaki, et al.
Publicado: (2020)

DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer
por: Board, Ruth E, et al.
Publicado: (2008)

Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma
por: Manzoni, Martina, et al.
Publicado: (2020)

Spontaneous Tumour Lysis Syndrome in a Multiple Myeloma
por: Huzmeli, Can, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_70krei9gs9kg55qdulvpjta693